Navigation Links
Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
Date:11/6/2012

CAMBRIDGE, Mass., Nov. 6, 2012 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of  beloranib.  This milestone follows the completion of three consecutive Phase 1b studies demonstrating rapid weight loss, reductions in body fat, improvements in cardiovascular risk factors and encouraging tolerability.

Beloranib, a novel therapy for obesity that utilizes a unique mechanism of action targeting methionine aminopeptidase 2 (MetAP2), is in development to assess its potential to safely and rapidly reduce body weight by restoring balance between the production and utilization of fat.

"This transition to larger and longer clinical trials is a significant milestone for Zafgen and for patients who suffer from severe obesity," Thomas Hughes, Ph.D., president and CEO of Zafgen, said.  "We are looking forward to learning more about the safety and efficacy of treatment with beloranib over a longer period of time.  Given the consistent and rapid weight loss we have observed with beloranib in previous studies, there appears to be significant potential to help severely obese patients, whose options are currently limited, to achieve a healthier weight and improve risk factors associated with type 2 diabetes and cardiovascular disease."

The first Phase 2a clinical trial will evaluate weight loss, safety and pharmacokinetics of beloranib administered twice a week.  Obese men and women with and without type 2 diabetes will receive subcutaneous injections for 12 weeks at eight participating centers.  The trial design is a randomized, double-blind, placebo-controlled study evaluating a range of doses in approximately 150 patients.

"Early results from clinical trials studying beloranib's effects on body weight and cardiovascular risk markers in obese patients have been very encourag
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel Announces Third Quarter 2012 Financial Results
2. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
3. Mindray Medical Announces Top Management Change
4. Cepheid Announces Executive Vice President Emerging Markets
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. PDL BioPharma Announces Third Quarter 2012 Financial Results
7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
8. Global Green, Inc. Announces DTC Eligibility
9. Psychemedics Corporation Announces 3rd Quarter Earnings
10. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
11. Life Sciences Entrepreneurs S.L.U. Announces the First Financing of the Antiplatelet Candidate NmC by Spanish and Swiss Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... a.m. EDT-, MONTVALE, N.J., Oct. 15 ... top-line data from the,multi-center, randomized, double-blind, placebo-controlled Phase ... channel modulator, in Alzheimer,s,disease. The trial enrolled 183 ... 40 centers in the United States and included ...
... Fla., Oct. 13 Acutely ill, hospitalized,patients ... taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared,to ... with INVEGA as early as five days ... the two-week study period, according to preliminary ...
Cached Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
(Date:12/25/2014)... risk of burns from fires and cooking accidents increases ... cautious, an expert says. "Between Thanksgiving and New ... coming in with burns," said Dr. Steven Sandoval, medical ... of Stony Brook University Hospital in New York. ... not careful, could quickly turn tragic," Sandoval said in ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... for First Quarter and Second Quarter ... and 2006 - - Company to Hold Conference Call on April ... $290.9 million, up 18.7% - ... April 23 Symmetry Medical Inc.,(NYSE: SMA ), a leading independent provider of ...
... 60 orders for faster form of image-guided ... intensity-modulated radiation therapy, PALO ALTO, Calif., ... announced it has received more than 60 orders for,its new ... have been,concentrated in North America but have also come in ...
... April 23 The NCCA accredited the ... Trainer,Certification for a five-year period, expiring March ... in 1992, NESTA is a professional certification ... and enforcing education,examination, experience and ethics requirements ...
... urges Senators Cardin and Mikulski to quickly pass,companion bill ... AARP thanked the,supporters and cosponsors of the Protecting ... in the U.S. House of Representatives. The bill,prevents massive ... cuts proposed by the administration., "Today,s vote is ...
... says goal is to maintain strength, not gain it, while ... you,re an athlete or fitness enthusiast who suffers a strained ... to stop exercising. , , "Exercise can definitely be beneficial ... type, the injured area should be moved and not left ...
... of Entries Available Through Charities and Tour Groups, ... announced today that,registration for the Bank of America ... on to complete the 26.2-mile race, marking the ... still available,through affiliated charities and tour groups., ...
Cached Medicine News:Health News:Symmetry Medical Reports Full Year 2007 Financial Results 2Health News:Symmetry Medical Reports Full Year 2007 Financial Results 3Health News:Symmetry Medical Reports Full Year 2007 Financial Results 4Health News:Symmetry Medical Reports Full Year 2007 Financial Results 5Health News:Symmetry Medical Reports Full Year 2007 Financial Results 6Health News:Symmetry Medical Reports Full Year 2007 Financial Results 7Health News:Symmetry Medical Reports Full Year 2007 Financial Results 8Health News:Symmetry Medical Reports Full Year 2007 Financial Results 9Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 2Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 3Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 5Health News:The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA) 2Health News:AARP Thanks Maryland's Representatives for Supporting Bill to Protect People in Medicaid 2Health News:Exercise Plays Role in Recovery From Sports Injuries 2Health News:2008 Bank of America Chicago Marathon Registration Closes as Race Reaches 45,000 Participant Capacity 2
Hartman Mosquito forceps, straight, 3 1/2"....
Curved 21 mm serrated jaws. Ring handle with ratchet lock. Non-magnetic and dull finish. Overall length 4.7 inches....
Straight shafts with 13 mm crisscross serrated platform with polished finish. Serrated handle....
Straight shafts with 15 mm long jaws. Serrated handle with polished finish. Crisscross jaws....
Medicine Products: